TITLE

Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer

AUTHOR(S)
Hajdenberg, Julio
PUB. DATE
December 2009
SOURCE
ACP Journal Club;12/15/2009, Vol. 151 Issue 6, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information about a study which says that continuous androgen-deprivation therapy (ADT) increases the risk for diabetes mellitus and fragility fractures in older men with prostate cancer. However, ADT is not associated with increased risk for myocardial infarction or sudden cardiac death. 38,158 prostate cancer patients of 66 years of age were selected from the Ontario Cancer Registry for the study.
ACCESSION #
47420857

 

Related Articles

  • ADT raises new-onset diabetes risk 43% in 1 year. Guttman, Cheryl // Urology Times;Sep2007, Vol. 35 Issue 11, p8 

    The article reports on the effects of androgen deprivation therapy (ADT) induction in men with prostate cancer in the U.S. The most notable effect is the increase on the risk of incident diabetes in a very short span of time. Dr. Richard Markus explained that the adverse physiological effects of...

  • Androgen-deprivation therapy linked to CV death, increased fractures.  // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p26 

    The article discusses research on the association of androgen-deprivation therapy used for treating prostate cancer with a elevated risk for skeletal fracture, incident diabetes and cardiovascular-related mortality, which references a study by L. G. Taylor published in a 2009 issue of "Cancer."

  • Background to and Management of Treatment-Related Bone Loss in Prostate Cancer. Berruti, A.; Tucci, M.; Terrone, C.; Gorzegno, G.; Scarpa, R.M.; Angeli, A.; Dogliotti, L. // Drugs & Aging;2002, Vol. 19 Issue 12, p899 

    Prostate cancer is a common disease among older men. Androgen suppression by either orchiectomy or administration of luteinising hormone-releasing hormone (LHRH) analogues is the mainstay of treatment. Since the use of prostate-specific antigen (PSA) serum testing has become widespread, however,...

  • Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients. Oliver, R T D; Farrugia, D; Ansell, W; Williams, G; Chinegwundoh, F // Prostate Cancer & Prostatic Diseases;2000, Vol. 3 Issue 4, p286 

    Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is...

  • Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Mousses, Spyro; Wagner, Urs; Chen, Yidong; Kim, J W; Bubendorf, Lukas; Bittner, Michael; Pretlow, Thomas; Elkahloun, Abdel G; Trepel, Jane B; Kallioniemi, Olli-P // Oncogene;10/11/2001, Vol. 20 Issue 46, p6718 

    Androgen deprivation therapy for advanced prostate cancer is often effective, but not curative. Molecular pathways mediating the therapeutic response and those contributing to the subsequent hormone-refractory cell growth remain poorly understood. Here, cDNA microarray analysis of human CWR22...

  • Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Sircar, K.; Gottlieb, B.; Alvarado, C.; Aprikian, A.; Beitel, L. K.; Alam-Fahmy, M.; Begin, L.; Trifiro, M. // Prostate Cancer & Prostatic Diseases;2007, Vol. 10 Issue 4, p360 

    To investigate contraction of CAG repeats within the androgen receptor gene (AR) as shorter CAG repeats have been implicated as a possible risk factor in prostate cancer (PCa). AR CAG repeat lengths were analyzed in DNA from microdissected diseased prostates, leukocytes from matched peripheral...

  • Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer. Jani, A. B.; Gratzle, J.; Myers, M. // Prostate Cancer & Prostatic Diseases;2005, Vol. 8 Issue 3, p224 

    Purpose: To analyze the impact of neoadjuvant hormone therapy (HT) on acute gastrointestinal (GI) and genitourinary (GU) toxicity from radiotherapy (RT).Scope: The toxicity rates of 480 consecutive prostate cancer patients were reviewed and compared using the χ2 test. Ordered logit...

  • Androgen deprivation is linked to gum disease.  // RN;Jun2007, Vol. 70 Issue 6, Special section p3 

    The article discusses research being done on androgen deprivation therapy. It references a study by P. Famili et al in a 2007 issue of the "Journal of Urology." The study found that men who are undergoing androgen deprivation therapy for prostate cancer are at a threefold increased risk of...

  • Hormone treatment for prostate cancer: current issues and future directions. Ichikawa, Tomohiko; Suzuki, Hiroyoshi; Ueda, Takeshi; Komiya, Akira; Imamoto, Takashi; Kojima, Satoko // Cancer Chemotherapy & Pharmacology. Supplement;Nov2005, Vol. 56, p58 

    Most prostate cancers are androgen-dependent and essentially respond to androgen ablation therapy. However, these tumors eventually become androgen-independent and progress despite androgen ablation. Since the androgen receptor (AR) sequence was determined, numerous studies have shown that AR...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics